Despite MannKind's share price surge, its P/S ratio is low due to a bleak revenue outlook. Shareholders accept this, anticipating no future revenue surprises. A turn of luck is needed for a higher P/S.
Analysts' forecasts reveal that MannKind Corporation's inferior revenue outlook is contributing to its lower P/S ratio. Shareholders accept this, cognizant that future revenue may not meet expectations, hence posing a hindrance for the share price at these levels.
MannKind's progress is recognized by the market and worth investor examination. However, two warning signs warrant attention. Strong share price momentum suggests opportunity.
曼恩凱德生物醫療股票討論區
$曼恩凱德生物醫療(MNKD.US)$
need to find out more
In reaction to earnings/guidance:
• $聯電(UMC.US)$ +0.8% (August revs)
Other news:
• $ChannelAdvisor(ECOM.US)$ +54.4% (to be acquired for $23.10 per share)
• $IVERIC bio(ISEE.US)$ +42.3% (topline data from Zimura GATHER2 phase 3 clinical trialingeographic atrophy)
• $Monte Rosa Therapeutics(GLUE.US)$ +10% (receives FDA clearance of Investigational New Drug Application for MRT-2359)
• $IDEAYA生物科學(IDYA.US)$ +4.9% (re...
• $Enphase Energy(ENPH.US)$ +8.2% (earnings reports)
• $Zentalis Pharmaceuticals(ZNTL.US)$ +7.6% (announces $25 mln equity investment from Pfizer (PFE); enters into development collaboration for ZN-c3)
• $特爾尼翁鋼鐵(TX.US)$ +6.1% (earnings reports)
• $PureCycle Technologies(PCT.US)$ +5% (SEC concludes investigation without further action)
• $Alliance Resource(ARLP.US)$ +4.7% (increases dividend; provides prelim qtrly results)
• $Digital World Acquisition Corp(DWAC.US)$ +4.5% (cu...
暫無評論